Transitioning patients taking infliximab to a biosimilar product and improving adherence to imatinib are among the strategies specialty pharmacists at Boston Medical Center Health System (BMC) used to help the health system better use health care resources, according to a workshop presentation during the 2020 NASP Annual Meeting & Expo Virtual Experience.
Shifting patients from originator infliximab to an infliximab biosimilar is forecasted to yield approximately $500,000 in annual savings,